Sign up to access all valuation multiples
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
2001
1.9K+
LTM Revenue $2.9B
LTM EBITDA $1.0B
$11.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sobi has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Sobi achieved revenue of $2.7B and an EBITDA of $970M.
Sobi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sobi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.7B | XXX | XXX | XXX |
| Gross Profit | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $1.0B | XXX | $970M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $672M | XXX | $584M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $457M | XXX | $404M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.6B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Sobi's stock price is SEK 291 (or $30).
Sobi has current market cap of SEK 100B (or $10.4B), and EV of SEK 112B (or $11.7B).
See Sobi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.7B | $10.4B | XXX | XXX | XXX | XXX | $1.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Sobi has market cap of $10.4B and EV of $11.7B.
Sobi's trades at 4.3x EV/Revenue multiple, and 12.0x EV/EBITDA.
Equity research analysts estimate Sobi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sobi has a P/E ratio of 22.8x.
See valuation multiples for Sobi and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.4B | XXX | $10.4B | XXX | XXX | XXX |
| EV (current) | $11.7B | XXX | $11.7B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.2x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBIT | 17.3x | XXX | 20.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.8x | XXX | 25.8x | XXX | XXX | XXX |
| EV/FCF | 21.9x | XXX | 25.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSobi's last 12 month revenue growth is 11%
Sobi's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.8M for the same period.
Sobi's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sobi's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sobi and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sobi acquired XXX companies to date.
Last acquisition by Sobi was XXXXXXXX, XXXXX XXXXX XXXXXX . Sobi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Sobi founded? | Sobi was founded in 2001. |
| Where is Sobi headquartered? | Sobi is headquartered in Sweden. |
| How many employees does Sobi have? | As of today, Sobi has 1.9K+ employees. |
| Who is the CEO of Sobi? | Sobi's CEO is Mr. Guido Oelkers. |
| Is Sobi publicy listed? | Yes, Sobi is a public company listed on STO. |
| What is the stock symbol of Sobi? | Sobi trades under SOBI ticker. |
| When did Sobi go public? | Sobi went public in 2006. |
| Who are competitors of Sobi? | Similar companies to Sobi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sobi? | Sobi's current market cap is $10.4B |
| What is the current revenue of Sobi? | Sobi's last 12 months revenue is $2.9B. |
| What is the current revenue growth of Sobi? | Sobi revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Sobi? | Current revenue multiple of Sobi is 4.1x. |
| Is Sobi profitable? | Yes, Sobi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sobi? | Sobi's last 12 months EBITDA is $1.0B. |
| What is Sobi's EBITDA margin? | Sobi's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Sobi? | Current EBITDA multiple of Sobi is 11.2x. |
| What is the current FCF of Sobi? | Sobi's last 12 months FCF is $534M. |
| What is Sobi's FCF margin? | Sobi's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Sobi? | Current FCF multiple of Sobi is 21.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
